Purple Biotech (PPBT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Purple Biotech has successfully closed a $2.8 million registered direct offering of American Depositary Shares, with H.C. Wainwright & Co. acting as the exclusive placement agent. The funds will be used to advance the development of their oncology therapeutic candidates and support general corporate activities. Investors interested in biotech innovations and oncology therapies might find opportunities with Purple Biotech’s continued progress in overcoming tumor immune evasion and drug resistance.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Oppenheimer Pounds the Table on Coinbase Stock
- New “Anti-Woke” ETF Targets Starbucks (NASDAQ:SBUX)
- Ford (NYSE:F) Plans New EV Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
